Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders

Translational Psychiatry

Volumn 1, Issue , 2011, Pages

  Tang, B ^a   Dean, B ^b,c   Thomas, E A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

bipolar disorder; chromatin; epigenetic; HDAC inhibitor; schizophrenia

Indexed keywords

HISTONE; HISTONE DEACETYLASE INHIBITOR;

ACETYLATION; ADOLESCENT; ADULT; AGED; AGING; ANIMAL; ARTICLE; BIPOLAR DISORDER; COMPARATIVE STUDY; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOUSE; PATHOPHYSIOLOGY; PROMOTER REGION; SCHIZOPHRENIA;

ACETYLATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; ANIMALS; BIPOLAR DISORDER; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MALE; MICE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84255200543     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2011.61     Document Type: Article

References (71)

1. Quina AS, Buschbeck M, Di Croce L. Chromatin structure and epigenetics. Biochem Pharmacol2006; 72:1563-1569. (Pubitemid 44666736)
2. Attwood JT, Yung RL, Richardson BC. DNA methylation and the regulation of gene transcription. Cell Mol Life Sci2002; 59: 241-257. (Pubitemid 34169512)
3. Kouzarides T. Chromatin modifications and theirfunction. Cell2007; 128: 693-705.
4. Akbarian S. The molecular pathology of schizophrenia-focus on histone and DNA modifications. Brain Res Bull2010; 83:103-107.
5. Deutsch SI, Rosse RB, Mastropaolo J, Long KD, Gaskins BL. Epigenetic therapeutic strategies for the treatment of neuropsychiatric disorders: ready for prime time? Clin Neuropharmacol 2008;31:104-119. (Pubitemid 351489337)
6. Roth TL, Lubin FD, Sodhi M, Kleinman JE. Epigenetic mechanisms in schizophrenia. Biochim Biophys Acta 2009; 1790: 869-877.
7. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8: 355-367. (Pubitemid 46652469)
8. Carrard A, Salzmann A, Malafosse A, Karege F. Increased DNA methylation status of the serotonin receptor 5HTR1A gene promoter in schizophrenia and bipolar disorder. JAffect Disord 2011; 132: 450-453.
9. Abdolmaleky HM, Yaqubi S, Papageorgis P, Lambert AW, Ozturk S, Sivaraman V et al. Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophr Res 2011; 129:183-190.
10. Chen Y, Dong E, Grayson DR. Analysis of the GAD1 promoter: trans-acting factors and DNA methylation converge on the 5' untranslated region. Neuropharmacology 2011; 60: 1075-1087.
11. Huang HS, Akbarian S. GAD1 m RNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLo S One 2007; 2: e809.
12. Abdolmaleky HM, Cheng KH, Russo A, Smith CL, Faraone SV, Wilcox M et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 2005; 134B: 60-66. (Pubitemid 40411111)
13. Grayson DR, Jia X, Chen Y, Sharma RP, Mitchell CP, Guidotti A et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci U S A 2005; 102: 9341-9346. (Pubitemid 40923565)
14. Abdolmaleky HM, Cheng KH, Faraone SV, Wilcox M, Glatt SJ, Gao F et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet2006; 15: 3132-3145. (Pubitemid 44607800)
15. Petronis A, Gottesman II, Kan P, Kennedy JL, Basile VS, Paterson AD et al. Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? Schizophr Bull 2003; 29:169-178. (Pubitemid 36871068)
16. Iwamoto K, Bundo M, Yamada K, Takao H, Iwayama-Shigeno Y, Yoshikawa T et al. DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. J Neurosci 2005; 25: 5376-5381. (Pubitemid 40770917)
17. Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet2008; 82: 696-711. (Pubitemid 351726115)
18. Akbarian S, Ruehl MG, Bliven E, Luiz LA, Peranelli AC, Baker SP et al. Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry2005; 62: 829-840. (Pubitemid 41126876)
19. Mirnics K, Levitt P, Lewis DA. Critical appraisal of DNA microarrays in psychiatric genomics. Biol Psychiatry2006; 60:163-176.
20. Thomas EA. Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders. Mol Neurobiol 2006; 34:109-128. (Pubitemid 46594649)
21. Pokholok DK, Harbison CT, Levine S, Cole M, Hannett NM, Lee TI et al. Genome-wide map of nucleosome acetylation and methylation in yeast. Cell2005; 122: 517-527. (Pubitemid 41191151)
22. Hill C, Keks NA, Roberts S, Opeskin K, Dean B, Copolov DL. Postmortem brain studies in schizophrenia: the problems of diagnosis. Am J Psychiatry 1996; 153: 533-537. (Pubitemid 26113318)
23. Stan AD, Ghose S, Gao XM, Roberts RC, Lewis-Amezcua K, Hatanpaa KJ et al. Human postmortem tissue: what quality markers matter? Brain Res 2006; 1123:1-11.
24. Luo RX, Postigo AA, Dean DC Rb interacts with histone deacetylase to repress transcription. Cell1998; 92: 463-473. (Pubitemid 28101110)
25. Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R et al. The HDAC inhibitor, 4b, ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci U S A 2008; 105: 15564-15569.
26. Desplats PA, Kass KE, Gilmartin T, Stanwood GD, Woodward EL, Head SR et al. Selective deficits in the expression of striatal-enriched m RNAs in Huntington's disease. J Neurochem 2006; 96:743-757.
27. Narayan S, Kass K, Thomas EA. Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte-related genes in the mouse brain. J Neurosci Res 2006; 85:757-765. (Pubitemid 46426075)
28. Sharov AA, Dudekula DB, Ko MS. A web-based tool for principal component and significance analysis of microarray data. Bioinformatics 2005; 21: 2548-2549. (Pubitemid 40731623)
29. Benjamini Y, Hochberg Y. Controlling the false discovery rate\-a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289-300.
30. Narayan S,Tang B, Head SR, Gilmartin TJ, Sutcliffe JG, Dean B et al. Molecular profilesof schizophrenia in the CNS at different stages of illness. Brain Res 2008; 1239: 235-248.
31. Kim S, Webster MJ. The stanley neuropathology consortium integrative database: a novel, web-based tool for exploring neuropathological markers in psychiatric disorders and the biological processes associated with abnormalities of those markers. Neuropsycho pharmacology 2010;35: 473-482.
32. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 2008; 28: 264-278.
33. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000; 28: 53-67.
34. Akbarian S, Huang HS. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev2006; 52: 293-304. (Pubitemid 44291805)
35. Marazziti D, Baroni S, Picchetti M, Landi P, Silvestri S, Vatteroni E et al. Mitochondrial alterations and neuropsychiatric disorder. Curr Med Chem 2011; 18: 4715-4721.
36. Torkamani A, Dean B, Schork NJ, Thomas EA. Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Res 2010; 20: 403-412.
37. Tang B, Chang WL, Lanigan CM, Dean B, Sutcliffe JG, Thomas EA. Normal human aging and early-stage schizophrenia share common molecular profiles. Aging Cell2009; 8: 339-342.
38. Thomas EA. Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors. Mol Neurobiol 2009; 40: 33-45.
39. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008; 7: 854-868.
40. Grayson DR, Kundakovic M, Sharma RP. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol2010; 77:126-135.
41. Chou CJ, Herman D, Gottesfeld JM. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem 2008; 283: 35402-35409.
42. Akbarian S, Huntsman MM, Kim JJ,Tafazzoli A, Potkin SG, Bunney Jr WE et al. GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls. Cereb Cortex1995; 5: 550-560. (Pubitemid 3005235)
43. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney Jr WE et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics [see comments]. Arch Gen Psychiatry 1995; 52: 258-266.
44. Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl) 2005; 180:191-205. (Pubitemid 40909664)
45. Cheung I, Shulha HP, Jiang Y, Matevossian A, Wang J, Weng Z et al. Developmental regulation and individual differences of neuronal H3K4me3 epigenomes in the prefrontal cortex. Proc Natl Acad Sci U SA 2010; 107: 8824-8829.
46. Oberdoerffer P, Sinclair DA. The role of nuclear architecture in genomic instability and ageing. Nat Rev Mol Cell Biol 2007; 8: 692-702. (Pubitemid 47312825)
47. Hernandez DG, Nalls MA, Gibbs JR, Arepalli S, van der Brug M, Chong S et al. Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum Mol Genet2011; 20:1164-1172.
48. Takasugi M. Progressive age-dependent DNA methylation changes start before adulthood in mouse tissues. Mech Ageing Dev2011; 132: 65-71.
49. Siegmund KD, Connor CM, Campan M, Long TI, Weisenberger DJ, Biniszkiewicz D et al. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLo S One 2007; 2: e895.
50. Sedivy JM, Banumathy G, Adams PD. Aging by epigenetics-a consequence of chromatin damage? Exp Cell Res 2008; 314:1909-1917.
51. Colantuoni C, Hyde TM, Mitkus S, Joseph A, Sartorius L, Aguirre C et al. Age-related changes in the expression of schizophrenia susceptibility genes in the human prefrontal cortex. Brain Struct Funct2008; 213: 255-271.
52. Kozurkova M, Misurova E, Kropacova K. Effect of aging and gamma radiation on acetylation of rat liver histones. Mech Ageing Dev 1995; 78:1-14.
53. Commerford SL, Carsten AL, Cronkite EP. Histone turnover within nonproliferating cells. Proc Natl Acad Sci USA1982;79:1163-1165. (Pubitemid 12105567)
54. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004; 64:1079-1086. (Pubitemid 38176913)
55. Wassef AA, Dott SG, Harris A, Brown A, O'Boyle M, Meyer 3rd WJ et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol2000; 20: 357-361. (Pubitemid 30318366)
56. Wassef AA, Hafiz NG, Hampton D, Molloy M. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J Clin Psychopharmacol2001; 21: 21-26. (Pubitemid 32096746)
57. Citrome L. Schizophrenia and valproate. Psychopharmacol Bull2003; 37(Suppl 2): 74-88.
58. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsycho pharmacology 2003; 28:182-192.
59. Citrome L. Adjunctive lithium and anticonvulsants forthe treatment of schizophrenia: what is the evidence? Expert Rev Neurother2009; 9: 55-71.
60. Casey DE, Daniel DG, Tamminga C, Kane JM, Tran-Johnson T, Wozniak P et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsycho pharmacology 2009; 34:1330-1338.
61. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009; 459: 55-60.
62. Mc Quown SC, Barrett RM, Matheos DP, Post RJ, Rogge GA, Alenghat T et al. HDAC3 is a critical negative regulator of long-term memory formation. J Neurosci 2011; 31: 764-774.
63. Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol 2008; 3: 41-66. (Pubitemid 351488276)
64. van der Werf M, van Boxtel M, Verhey F, Jolles J, Thewissen V, van Os J. Mild hearing impairment and psychotic experiences in a normal aging population. Schizophr Res 2007; 94: 180-186. (Pubitemid 47033976)
65. von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med 2005;5:197-203. (Pubitemid 40601647)
66. Miller KR, Streit WJ. The effects of aging, injury and disease on microglial function: a case for cellular senescence. Neuron Glia Biol2007; 3: 245-253. (Pubitemid 351594233)
67. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry1999; 46: 729-739. (Pubitemid 29460898)
68. Witthaus H, Brune M, Kaufmann C, Bohner G, Ozgurdal S, Gudlowski Yet al. White matter abnormalities in subjects at ultra high-risk for schizophrenia and first-episode schizophrenic patients. Schizophr Res 2008; 102:141-149.
69. Steen RG, Mull C, Mc Clure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry2006; 188: 510-518. (Pubitemid 43844097)
70. Fernandez-Egea E, Bernardo M, Heaphy CM, Griffith JK, Parellada E, Esmatjes E et al. Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr Bull2009; 35: 437-442.
71. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008; 64: 820-822.